Reduced integrin α3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung
Reduced integrin α3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung
复制标题
DOI：
10.1200/jco.1998.16.3.1060
复制
发表时间：
1998-03-01
影响因子：
45.3
通讯作者：
Miyake, M
中科院分区：
文献类型：
--
作者：
Adachi, M;Taki, T;Miyake, M
目的：探讨整合素- 3与非小细胞肺癌（NSCLC）中运动相关蛋白（MRP-1）、分化抗原簇9 （CD9）基因表达的关系，并评价整合素- 3表达对预后的影响。患者和方法：我们使用定量逆转录酶聚合酶链反应（RT-PCR）和免疫组织化学对151例非小细胞肺癌患者切除肿瘤组织中整合素α 3和MRP-1/CD9的表达进行了回顾性研究。结果：整合素α 3/ β -肌动蛋白表达比值范围为0 ~ 5.87（平均值0.80，中位数0.70）。截止值为0.7，整合素α 3阳性肿瘤78例（52%），整合素α 3表达降低肿瘤73例（48%）。免疫组化结果与RT-PCR结果吻合较好，88%无差异，如有差异，采用RT-PCR结果进行标本分类。整合素α 3基因表达独立于MRP-1/CD9基因表达。整合素- 3的表达与患者的临床特征无显著相关性。整合素α 3阳性nsclc患者的总生存率仅略高于整合素α 3表达降低的个体（55.9% vs 47.1%; P = 0.085）。相比之下，整合素α 3阳性腺癌患者的总生存率显著高于基因表达降低的患者（54.4% vs 35.2%； P= 0.004）。采用非小细胞肺癌和腺癌的Cox回归模型进行多因素分析显示，除淋巴结状态外，整合素α 3表达与总生存率的相关性较好（P = 0.0188和P= 0.0008）。结论：肺癌组织中整合素- 3与MRP-1/CD9基因表达无显著相关性。然而，在腺癌患者中，整合素- 3表达降低是一个预后不良的因素。(C)美国临床肿瘤学会1998。
Purpose: We investigated the possible association between integrin alpha 3 and motility-related protein (MRP-1), cluster of differentiation antigen 9 (CD9) gene expression in non-small-cell lung cancer (NSCLC) and evaluated the prognostic significance of integrin alpha 3 expression.Patients and Methods: We performed a retrospective study of integrin alpha 3 and MRP-1/CD9 expression in resected tumor tissues from 151 NSCLC patients using quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry.Results: The ratio of integrin alpha 3/beta-actin expression ranged from 0 to 5.87 (mean was 0.80; median, 0.70). Using the cutoff value of 0.7, there were 78 (52%) integrin alpha 3-positive tumors and 73 (48%) tumors with reduced integrin alpha 3 expression. The immunohistochemical results agreed well with those of the RT-PCR assays, and 88% had no discrepancy, In case of discrepancy, the results of RT PCR were used in specimen classification. Integrin alpha 3 gene expression was independent from MRP-1/CD9 gene expression. No significant association was found between integrin alpha 3 expression and the patients' clinical characteristics. The overall survival rate of patients with integrin alpha 3-positive NSCLCs was only slightly better than that of individuals whose tumors had reduced integrin alpha 3 expression (55.9% v 47.1%; P =.085). By comparison, the overall survival rate of patients with integrin alpha 3-positive adenocarcinomas was strikingly greater than in those whose tumors had reduced gene expression (54.4% v 35.2%; P=.004). Multivariate analysis with the Cox regression model of NSCLC and adenocarcinoma indicated that integrin alpha 3 expression correlated better (P =.0188 and P=.0008, respectively) with the overall survival rate than other variables, except lymph node status.Conclusion: No significant association was found between integrin alpha 3 and MRP-1/CD9 gene expression in lung cancer. However, reduced integrin alpha 3 expression is a poor prognosis factor in patients with adenocarcinomas. (C) 1998 by American Society of Clinical Oncology.